All Stories

  1. Lactate‐mediated activation of GPR81 regulates BCR /Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tension

    Article • The Journal of Pathology, October 2025, Wiley

    Elisabetta Rovida

  2. Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Cancer?

    Article • International Journal of Molecular Sciences, August 2025, MDPI AG

    Elisabetta Rovida

  3. Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Can-Cer?

    Article • June 2025, MDPI AG

    Elisabetta Rovida

  4. VCAN is essential for ERK5-driven tumorigenesis in soft tissue sarcoma

    Article • May 2025, openRxiv

    Elisabetta Rovida

  5. BCR::ABL1 expression in chronic myeloid leukemia cells in low oxygen is regulated by glutamine via CD36-mediated fatty acid uptake

    Article • Cancer Cell International, May 2025, Springer Science + Business Media

    Elisabetta Rovida

  6. Exploring the Gut Microbiota–Retina Axis: Implications for Health and Disease

    Article • Microorganisms, May 2025, MDPI AG

    Dr Emiliano Antiga, Elisabetta Rovida

  7. The MEK5/ERK5 pathway promotes the activation of the Hedgehog/GLI signaling in melanoma cells

    Article • Cellular Oncology, February 2025, Springer Science + Business Media

    Elisabetta Rovida

  8. Liquid Crystalline Networks Hamper the Malignancy of Cancer Cells

    Article • Advanced Healthcare Materials, January 2025, Wiley

    Elisabetta Rovida

  9. Ganglioside GD2 Contributes to a Stem‐Like Phenotype in Intrahepatic Cholangiocarcinoma

    Article • Liver International, December 2024, Wiley

    Elisabetta Rovida

  10. Altered fatty acid metabolism rewires cholangiocarcinoma stemness features

    Article • JHEP Reports, October 2024, Elsevier

    Elisabetta Rovida

  11. ERK5 mediates pro-tumorigenic phenotype in non-small lung cancer cells induced by PGE2

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, October 2024, Elsevier

    Elisabetta Rovida

  12. Latent-Transforming Growth Factor β-Binding Protein 1/Transforming Growth Factor β1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma

    Article • American Journal Of Pathology, August 2024, Elsevier

    Elisabetta Rovida

  13. Importin subunit beta‐1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation

    Article • Molecular Oncology, July 2024, Wiley

    Elisabetta Rovida

  14. Sphingosine 1‐phosphate elicits a ROS‐mediated proinflammatory response in human endometrial stromal cells via ERK5 activation

    Article • The FASEB Journal, June 2023, Wiley

    Dr Silvia Vannuccini, Elisabetta Rovida

  15. Pathophysiological Impact of the MEK5/ERK5 Pathway in Oxidative Stress

    Article • Cells, April 2023, MDPI AG

    Elisabetta Rovida

  16. Anti‐β4 integrin autoantibodies in patients with mucous membrane pemphigoid: A retrospective analysis from a tertiary centre in Italy

    Article • Journal of the European Academy of Dermatology and Venereology, October 2022, Wiley

    Elisabetta Rovida

  17. MAPK15 protects from oxidative stress‐dependent cellular senescence by inducing the mitophagic process

    Article • Aging Cell, June 2022, Wiley

    Elisabetta Rovida

  18. Targeting MAPK in Cancer 2.0

    Article • International Journal of Molecular Sciences, May 2022, MDPI AG

    Elisabetta Rovida

  19. Lactate Maintains BCR/Abl Expression and Signaling in Chronic Myeloid Leukemia Cells Under Nutrient Restriction

    Article • Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, May 2022, Computers, Materials and Continua (Tech Science Press)

    Elisabetta Rovida

  20. Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators

    Article • JHEP Reports, April 2022, Elsevier

    Elisabetta Rovida

  21. Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation

    Article • Cellular and Molecular Gastroenterology and Hepatology, January 2022, Elsevier

    Elisabetta Rovida

  22. Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21

    Article • Cancer Research, November 2021, American Association for Cancer Research (AACR)

    Elisabetta Rovida

  23. The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells

    Article • International Journal of Molecular Sciences, October 2021, MDPI AG

    Elisabetta Rovida

  24. Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential

    Article • Cancers, August 2021, MDPI AG

    Elisabetta Rovida

  25. Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells

    Article • Hepatology, July 2021, Wolters Kluwer Health

    Elisabetta Rovida

  26. Playing the Whack-A-Mole Game: ERK5 Activation Emerges Among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2- Targeted Therapy

    Article • Frontiers in Cell and Developmental Biology, March 2021, Frontiers

    Elisabetta Rovida

  27. Enhanced Antitumoral Activity and Photoacoustic Imaging Properties of AuNP‐Enriched Endothelial Colony Forming Cells on Melanoma

    Article • Advanced Science, December 2020, Wiley

    Elisabetta Rovida

  28. In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features

    Article • Targeted Oncology, August 2020, Springer Science + Business Media

    Elisabetta Rovida

  29. Abstracts of the 2nd AMP Europe Congress

    Article • Journal of Molecular Diagnostics, May 2020, Elsevier

    Elisabetta Rovida

  30. Fatty acids regulate the biology of cholangiocarcinoma cells

    Article • Digestive and Liver Disease, February 2020, Elsevier

    Elisabetta Rovida

  31. Beyond Kinase Activity: ERK5 Nucleo-Cytoplasmic Shuttling as a Novel Target for Anticancer Therapy

    Article • International Journal of Molecular Sciences, January 2020, MDPI AG

    Elisabetta Rovida

  32. The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells

    Article • Oncogenesis, October 2019, Springer Science + Business Media

    Elisabetta Rovida

  33. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma

    Article • American Journal Of Pathology, October 2019, Elsevier

    Elisabetta Rovida

  34. CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, September 2019, Elsevier

    Elisabetta Rovida

  35. Poster Presentations: Posters Saturday, 13 April 2019

    Article • Journal of Hepatology, April 2019, Elsevier

    Elisabetta Rovida

  36. Impact of ERK5 on the Hallmarks of Cancer

    Article • International Journal of Molecular Sciences, March 2019, MDPI AG

    Elisabetta Rovida

  37. Ganglioside composition correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cell adhesion

    Article • Digestive and Liver Disease, February 2019, Elsevier

    Elisabetta Rovida

  38. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells

    Article • Stem Cell Reports, October 2018, Elsevier

    Elisabetta Rovida

  39. ERK5 is activated by oncogenic BRAF and promotes melanoma growth

    Article • Oncogene, February 2018, Nature

    Elisabetta Rovida

  40. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine

    Article • Blood, June 2017, American Society of Hematology

    Elisabetta Rovida

  41. The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction

    Article • Stem Cells International, January 2017, Hindawi Publishing Corporation

    Nathalie Mazure, Elisabetta Rovida, Matteo Lulli

  42. Low-dose methotrexate enhances cycling of highly anaplastic cancer cells

    Article • Cell Cycle, November 2016, Taylor & Francis

    Elisabetta Rovida

  43. Different BCR/Abl protein suppression patterns as a converging trait of Chronic Myeloid Leukemia cell adaptation to energy restriction

    Article • Oncotarget, November 2016, Impact Journals, LLC

    Elisabetta Rovida

  44. Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway

    Article • Cell Adhesion & Migration, September 2016, Taylor & Francis

    Elisabetta Rovida

  45. Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells

    Article • Frontiers in Oncology, April 2016, Frontiers

    Elisabetta Rovida

  46. Crosstalk between MAPK and HH_GLI signaling in cancer

    Article • Seminars in Cancer Biology, December 2015, Elsevier

    Elisabetta Rovida

  47. The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents

    Article • Oncotarget, October 2015, Impact Journals, LLC

    Elisabetta Rovida

  48. Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells

    Article • Cell Cycle, October 2015, Taylor & Francis

    Elisabetta Rovida

  49. PGE2 synergizes with CSF-1R

    Article • The FASEB Journal, March 2015, Federation of American Societies For Experimental Biology (FASEB)

    Professor Sandra Donnini, Elisabetta Rovida

  50. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells

    Article • Oncotarget, February 2015, Impact Journals, LLC

    Elisabetta Rovida

  51. Positive correlation of HIF2α and SERPINB3 in human hepatocellular carcinoma: selectivity and prognostic implications

    Article • Digestive and Liver Disease, February 2015, Elsevier

    Elisabetta Rovida

  52. Colony-Stimulating Factor-1 Receptor in the Polarization of Macrophages: A Target for Turning Bad to Good Ones?

    Article • Journal of Clinical & Cellular Immunology, January 2015, OMICS Publishing Group

    Elisabetta Rovida

  53. Lipid rafts: integrated platforms for vascular organization offering therapeutic opportunities

    Article • Cellular and Molecular Life Sciences, January 2015, Springer Science + Business Media

    Elisabetta Rovida

  54. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy

    Article • Cell Cycle, October 2014, Taylor & Francis

    Elisabetta Rovida

  55. The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma

    Article • Gut, September 2014, BMJ

    Elisabetta Rovida

  56. 786: The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma

    Article • European Journal of Cancer, July 2014, Elsevier

    Elisabetta Rovida

  57. Possible mechanisms and function of nuclear trafficking of the colony-stimulating factor-1 receptor

    Article • Cellular and Molecular Life Sciences, June 2014, Springer Science + Business Media

    Elisabetta Rovida

  58. P94 c-Rel AND p27Kip ARE DOWNSTREAM TARGETS OF ERK5 IN HEPATOCELLULAR CARCINOMA (HCC) IN VIVO AND IN VITRO

    Article • Journal of Hepatology, April 2014, Elsevier

    Elisabetta Rovida

  59. One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment

    Article • Hypoxia, January 2014, Taylor & Francis

    Elisabetta Rovida

  60. Chromatin-associated CSF-1R binds to the promoter of proliferation-related genes in breast cancer cells

    Article • Oncogene, December 2013, Nature

    Elisabetta Rovida

  61. Correction to Barbetti V, et al. Epigenetics Volume 8, Issue 2; pp. 210–9

    Article • Epigenetics, December 2013, Taylor & Francis

    Elisabetta Rovida

  62. Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets

    Article • Cell Cycle, November 2013, Taylor & Francis

    Elisabetta Rovida

  63. The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells

    Article • Current Pharmaceutical Design, July 2013, Bentham Science Publishers

    Elisabetta Rovida

  64. 1039 ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN KINASE ERK5 REGULATES THE DEVELOPMENT AND GROWTH OF HEPATOCELLULAR CARCINOMA

    Article • Journal of Hepatology, April 2013, Elsevier

    Elisabetta Rovida

  65. AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia

    Article • Cell Death and Disease, March 2013, Nature

    Elisabetta Rovida

  66. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells

    Article • Epigenetics, February 2013, Taylor & Francis

    Elisabetta Rovida

  67. The involvement of a Nanog, Klf4 and c-Myc transcriptional circuitry in the intertwining between neoplastic progression and reprogramming

    Article • Cell Cycle, January 2013, Taylor & Francis

    Elisabetta Rovida

  68. 78O_PR The Role of Ap-1 in Endocrine-Resistant Breast Cancer

    Article • Annals of Oncology, May 2012, Elsevier

    Elisabetta Rovida

  69. The Colony-Stimulating Factor-1 (CSF-1) Receptor Sustains ERK1/2 Activation and Proliferation in Breast Cancer Cell Lines

    Article • PLOS One, November 2011, PLOS

    Elisabetta Rovida

  70. Hypoxia Selects Bortezomib-Resistant Stem Cells of Chronic Myeloid Leukemia

    Article • PLOS One, February 2011, PLOS

    Elisabetta Rovida

  71. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate

    Article • Haematologica, November 2010, Ferrata Storti Foundation (Haematologica)

    Elisabetta Rovida

  72. Correction: Granulocyte Maturation after Butyrate Treatment of Leukemic Blasts

    Article • Cancer Research, November 2008, American Association for Cancer Research (AACR)

    Elisabetta Rovida

  73. p38 and cancer: Yang gets yin

    Article • Cancer Biology & Therapy, August 2008, Taylor & Francis

    Elisabetta Rovida

  74. ERK5/BMK1 Is Indispensable for Optimal Colony-Stimulating Factor 1 (CSF-1)-Induced Proliferation in Macrophages in a Src-Dependent Fashion

    Article • The Journal of Immunology, March 2008, The American Association of Immunologists

    Elisabetta Rovida

  75. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells

    Article • Journal of Hepatology, January 2008, Elsevier

    Elisabetta Rovida

  76. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells

    Article • Oncogene, September 2007, Nature

    Elisabetta Rovida

  77. Severe Hypoxia Defines Heterogeneity and Selects Highly Immature Progenitors Within Clonal Erythroleukemia Cells

    Article • Stem Cells, May 2007, Wiley

    Elisabetta Rovida

  78. The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells

    Article • British Journal of Haematology, December 2006, Wiley

    Elisabetta Rovida

  79. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations

    Article • Leukemia, May 2006, Nature

    Elisabetta Rovida

  80. 332 Activation of ERK5, a member of the mapk family, differentially regulates proliferation and migration of hepatic stellate cells

    Article • Journal of Hepatology, April 2006, Elsevier

    Elisabetta Rovida

  81. Focal adhesion kinase is redistributed to focal complexes and mediates cell spreading in macrophages in response to M-CSF

    Article • Biological Chemistry, January 2005, De Gruyter

    Elisabetta Rovida

  82. Corrections

    Article • Cancer Research, May 2004, American Association for Cancer Research (AACR)

    Elisabetta Rovida

  83. Tryptophan availability selectively limits NO-synthase induction in macrophages

    Article • Journal of Leukocyte Biology, January 2003, Society for Leukocyte Biology

    Elisabetta Rovida

  84. Low M r Phosphotyrosine Protein Phosphatase Associates and Dephosphorylates p125 Focal Adhesion Kinase, Interfering with Cell Motility and Spreading

    Article • Journal of Biological Chemistry, June 2002, American Society for Biochemistry & Molecular Biology (ASBMB)

    Elisabetta Rovida

  85. Opposite effects of different doses of MCSF on ERK phosphorylation and cell proliferation in macrophages

    Article • Oncogene, May 2002, Springer Science + Business Media

    Professor Manuela Baccarini, Elisabetta Rovida

  86. Transmodulation of Cell Surface Regulatory Molecules via Ectodomain Shedding

    Article • Biological Chemistry, January 2002, De Gruyter

    Elisabetta Rovida

  87. TNF- -Converting Enzyme Cleaves the Macrophage Colony-Stimulating Factor Receptor in Macrophages Undergoing Activation

    Article • The Journal of Immunology, February 2001, The American Association of Immunologists

    Elisabetta Rovida

  88. The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability

    Article • Leukemia, April 2000, Nature

    Elisabetta Rovida

  89. Incubation of murine bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors

    Article • British Journal of Haematology, February 2000, Wiley

    Elisabetta Rovida

  90. Low M r phosphotyrosine protein phosphatase activity on fibroblast growth factor receptor is not associated with enzyme translocation

    Article • FEBS Letters, October 1999, Wiley

    Elisabetta Rovida

  91. The Low-Molecular-Weight Phosphotyrosine Protein Phosphatase, when Overexpressed, Reduces the Mitogenic Response to Macrophage Colony-Stimulating Factor and Tyrosine Phosphorylation of Its Receptor

    Article • Biochemical and Biophysical Research Communications, December 1998, Elsevier

    Elisabetta Rovida

  92. INTERLEUKIN 2 DOWN-MODULATES THE MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR IN MURINE MACROPHAGES

    Article • Cytokine, June 1996, Elsevier

    Elisabetta Rovida